NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in September

About this update from Newamsterdam Pharma Company N.v.

NAARDEN, The Netherlands and MIAMI , Aug. 25, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present additional pooled safety and efficacy data from the pivotal Phase 3 BROADWAY and BROOKLYN trials at the European Society of Cardiology Congress (ESC), taking place August 29 – September 1, 2025 in Madrid, Spain . Additionally, NewAmsterdam announced that company management will participate in three upcoming investor conferences. Details are as follows: European Society of Cardiology Congress (ESC) 2025 Presentation Title: Efficacy of obicetrapib across the spectrum of background lipid lowering therapies-pooled analyses of the Broadway and Brooklyn randomized trials Session Title: Changing face of lipid-lowering therapy Presentation Date and Time: Friday, August 29, 2025 at 10:10am CEST Presenter: Kausik Ray , M.D. Presentation Title: Obicetrapib and cardiovascular events Session Title: Late-Breaking Clinical Science: lipids and cardiovascular risk Presentation Date and Time: Monday, September 1, 2025 at 9:00am CEST Presenter: Stephen Nicholls , M.D. Citi’s 2025 Biopharma Back to School Summit Fireside Chat Date and Time: Wednesday, September 3, 2025 at 2:30pm ET in Boston, MA Presenters: Michael Davidson , M.D., Chief Executive Officer, and Ian Somaiya , Chief Financial Officer Cantor Global Healthcare Conference 2025 Fireside Chat Date and Time: Thursday, September 4, 2025 at 2:45pm ET in New York, NY Presenters: Michael Davidson , M.D., Chief Executive Officer, and Ian Somaiya , Chief Financial Officer Wells Fargo Healthcare Conference Fireside Chat Date and Time: Friday, September 5, 2025 at 10:15am ET in Boston, MA Presenter: Ian Somaiya , Chief Financial Officer Live webcasts of the fireside chat presentations will be available through the investor relations section of the NewAmsterdam Pharma website at ir.newamsterdampharma.com . Following the live webcasts, archived replays will be available on the Company’s website. About NewAmsterdam NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated. Company Contact Matthew Philippe P: 1-917-882-7512 [email protected] Media Contact Real Chemistry on behalf of NewAmsterdam Christian Edgington P: 1-513-310-6410 [email protected] Investor Contact Precision AQ on behalf of NewAmsterdam Austin Murtagh P: 1-212-698-8696 [email protected] Source: NewAmsterdam Pharma N.V.

View stock analysis, news, and events for Newamsterdam Pharma Company N.v.